The U.S. Food and Drug Administration Accepts Supplemental NDA for Accelerated Evaluation, Setting a PDUFA Target Action Date of June 30, 2026
Ionis Pharmaceuticals, Inc. has announced a significant regulatory milestone for its investigational therapy olezarsen, as the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for Priority Review. The application seeks approval of olezarsen for the treatment of severe hypertriglyceridemia (sHTG), a serious lipid disorder associated with a markedly increased risk of acute pancreatitis and long-term health complications.
Under the Prescription Drug User Fee Act (PDUFA) framework, the FDA has set a target action date of June 30, 2026, for its decision on the application. The granting of Priority Review status shortens the FDA’s review timeline from the standard 10 months to approximately six months, reflecting the agency’s determination that olezarsen has the potential to offer a meaningful improvement in safety or effectiveness for patients facing a serious condition.
Addressing a Significant Unmet Medical Need
Severe hypertriglyceridemia is characterized by extremely elevated triglyceride levels, typically above 500 mg/dL and often exceeding 1,000 mg/dL. Patients with sHTG are at high risk of developing acute pancreatitis, a sudden and potentially life-threatening inflammation of the pancreas. Recurrent pancreatitis attacks can lead to chronic pancreatic damage, persistent abdominal pain, digestive complications, diabetes, and in some cases, organ failure or death.
Despite available lipid-lowering therapies, including fibrates, omega-3 fatty acids, niacin, and statins, many patients with sHTG struggle to achieve and maintain triglyceride levels below the threshold associated with pancreatitis risk. Standard-of-care treatments often provide limited efficacy in the most severe cases, leaving a substantial unmet need for therapies that can deliver profound triglyceride reductions and meaningfully lower the risk of acute pancreatitis.
Brett P. Monia, Ph.D., Chief Executive Officer of Ionis, emphasized the importance of the FDA’s decision. He noted that current treatment options frequently fail to adequately protect patients from recurrent and debilitating pancreatitis episodes, which can have serious and long-term health consequences. According to Monia, the FDA’s Priority Review designation underscores the urgent need for additional therapeutic options and positions olezarsen to potentially reach patients more rapidly if approved.
Ionis views this regulatory milestone as a pivotal step toward delivering what could become the first therapy demonstrated to reduce the risk of potentially life-threatening acute pancreatitis attacks in people with severe hypertriglyceridemia.
Clinical Evidence from Phase 3 CORE and CORE2 Studies
The sNDA submission and the FDA’s Priority Review decision are supported by robust data from the Phase 3 CORE and CORE2 clinical trials evaluating olezarsen in patients with sHTG. These pivotal studies assessed both the efficacy and safety of the therapy in a population at high risk for pancreatitis.
In the trials, olezarsen achieved a highly statistically significant placebo-adjusted reduction in triglyceride levels of up to 72%. Such reductions represent a substantial improvement over many currently available therapies and demonstrate the drug’s capacity to dramatically lower triglyceride concentrations in patients with severe disease.
Beyond triglyceride reduction, one of the most compelling findings from the CORE and CORE2 studies was an 85% reduction in acute pancreatitis events among patients treated with olezarsen compared to placebo. This outcome is particularly important because it addresses not only a laboratory parameter but also a clinically meaningful endpoint directly linked to patient morbidity and healthcare burden.
Additionally, nearly 90% of patients receiving olezarsen achieved triglyceride levels below 500 mg/dL. This level is widely recognized as the threshold below which the risk of acute pancreatitis is substantially reduced. Achieving this benchmark in such a high proportion of treated patients highlights olezarsen’s potential to fundamentally alter the management paradigm for sHTG.
The therapy also demonstrated favorable safety and tolerability profiles in the Phase 3 program, an essential consideration for a chronic condition that requires ongoing treatment. The overall balance of efficacy and safety played a critical role in supporting the regulatory submission and the FDA’s decision to grant Priority Review status.
The findings from the CORE and CORE2 trials were published in the prestigious The New England Journal of Medicine, further underscoring the scientific rigor and clinical importance of the data. The results were also presented at the American Heart Association Scientific Sessions, one of the leading global forums for cardiovascular research and innovation.
Regulatory Recognition and Breakthrough Therapy Designation
The FDA’s Priority Review designation is reserved for therapies that, if approved, could represent a significant advancement in the treatment, prevention, or diagnosis of serious conditions. By granting this status, the agency has signaled that olezarsen may offer clinically meaningful benefits over existing treatment options.
In addition to Priority Review, olezarsen previously received Breakthrough Therapy designation from the FDA in November 2025. Breakthrough Therapy designation is intended to expedite the development and review of drugs that show substantial improvement over available therapies based on preliminary clinical evidence. The combination of Breakthrough Therapy designation and Priority Review reflects strong regulatory recognition of the therapy’s potential impact.
Together, these designations may facilitate enhanced communication between Ionis and the FDA throughout the review process, as well as a faster path to potential approval and patient access.
